Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Novel Saltwater Treatment Device

Published: Monday, May 27, 2013
Last Updated: Monday, May 27, 2013
Bookmark and Share
Cambridge Consultants develops innovative nebulizer to treat cystic fibrosis.

Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease.

Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a revolutionary new aerosol delivery system.

It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.

“We have seen evidence that routine exposure to salt water reduces the number of lung infections in CF patients and leads to fewer hospital admissions - but the challenge was to develop an optimal delivery system,” said Dr Richard Boucher, co-founder and chairman of Parion.

Dr Boucher continued, “We enlisted Cambridge Consultants to design the system, given its track record of creating world firsts in drug delivery device development - and the results have exceeded our expectations.”

CF is a chronic disease that affects the lungs and digestive system of more than 70,000 adults and children worldwide. Studies have shown that the inhalation of a hypertonic saltwater solution improves the condition of sufferers by rehydrating the layer of mucus film that lines their lungs.

Cambridge Consultants conducted human-factor studies and applied its expertise in fluid dynamics to develop a system that could deliver an aerosol mist through the nose continuously for eight hours.

“We immediately recognized the potential of this project to transform the lives of CF patients,” said Matthew Allen, programme director at Cambridge Consultants. “The challenge was to build an aerosol nebulizer system that could be comfortably used by patients overnight - with the saline mist travelling down a long cannula to the sleeping patient without forming the large droplets that often occur in a standard nebulizer system. The size of the saline droplets is crucial to the success of the treatment as they need to be small enough to penetrate deep into the lungs.”

The tPAD (trans-nasal pulmonary aerosol delivery) device has been assessed in a clinical trial - and so greatly exceeded its predicted performance that additional devices have now been requested to support further clinical trials.

The aim is to provide an easy and effective treatment system for CF patients that is suitable even for young children and allows the disease to be treated at the earliest possible stages.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos